Genomictree Inc
KOSDAQ:228760
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Genomictree Inc
Total Liabilities
Genomictree Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genomictree Inc
KOSDAQ:228760
|
Total Liabilities
₩7.2B
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Liabilities
₩5.1T
|
CAGR 3-Years
43%
|
CAGR 5-Years
25%
|
CAGR 10-Years
17%
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Total Liabilities
₩7.2B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Liabilities
₩253.5B
|
CAGR 3-Years
38%
|
CAGR 5-Years
55%
|
CAGR 10-Years
77%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Total Liabilities
₩126.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
69%
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Total Liabilities
₩27.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Genomictree Inc
Glance View
Genomictree, Inc. engages in the development and supply of diagnostic products for cancer screening and prognosis. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2016-07-19. The firm is involved in conducting of genomic analysis using microarrays and next generation sequencing analysis. In addition, the Company is conducting clinical trials for molecular diagnostic products. Molecular diagnostic products include cancer molecular diagnostic products and molecular genetic diagnostic products. Cancer molecular diagnostic products include molecular diagnostic products for colorectal cancer, bladder cancer, lung cancer, stomach cancer, cervical cancer. Molecular genetic diagnostic products include epidermal growth factor receptor (EGFR) mutation diagnosis, as well as human papilloma virus (HPV) diagnostic products.
See Also
What is Genomictree Inc's Total Liabilities?
Total Liabilities
7.2B
KRW
Based on the financial report for Sep 30, 2025, Genomictree Inc's Total Liabilities amounts to 7.2B KRW.
What is Genomictree Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
-21%
Over the last year, the Total Liabilities growth was -14%. The average annual Total Liabilities growth rates for Genomictree Inc have been -50% over the past three years , -21% over the past five years .
